4.5 Article

Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS)

期刊

OSTEOPOROSIS INTERNATIONAL
卷 24, 期 10, 页码 2591-2601

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s00198-013-2349-y

关键词

Bisphosphonate; Bone microstructure; Cortical; High-resolution peripheral quantitative computed tomography; Parathyroid hormone; Trabecular

资金

  1. Genentech, Inc.
  2. NPS Pharmaceuticals [PTH[1-84]]
  3. Genentech
  4. Bayer
  5. Department of Veterans Affairs through an Advanced Fellowship in Women's Health
  6. Career Development Award [5 IK2 CX000549-02]
  7. Research Enhancement Award Program
  8. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [R01-AR055588, R01-AR060700]
  9. NIAMS
  10. National Institute on Aging
  11. National Institute of Biomedical Imaging and Bioengineering [R01-AG017762]

向作者/读者索取更多资源

In postmenopausal women receiving combination parathyroid hormone (PTH) (1-84) therapy and ibandronate, we evaluated bone microarchitecture and biomechanics using high-resolution peripheral quantitative computed tomography (HR-pQCT). Cortical and trabecular changes were different at the nonweight-bearing radius vs. the weight-bearing tibia, with more favorable overall changes at the tibia. Introduction PTH therapy and bisphosphonates decrease fracture risk in postmenopausal osteoporosis, but their effects on bone microstructure and strength have not been fully characterized, particularly during combination therapy. PTH increases trabecular bone mineral density (BMD) substantially but may decrease cortical BMD, possibly by stimulating intracortical remodeling. We evaluated bone microarchitecture and biomechanics with HR-pQCT at the radius (a nonweight-bearing site) and tibia (weight bearing) in women receiving combination PTH(1-84) and ibandronate. Methods Postmenopausal women with low bonemass (n=43) were treated with 6 months of PTH(1-84) (100 mu g/day), either as one 6- or two 3-month courses, in combination with ibandronate (150 mg/month) over 2 years. HR-pQCT was performed before and after therapy. Results Because changes in HR-pQCT parameters did not differ between treatment arms, groups were pooled into one cohort for analysis. Trabecular BMD increased at both radius and tibia (p<0.01 for each). Cortical thickness and BMD decreased at the radius (p<0.01), consistent with changes in dual-energy X-ray absorptiometry, while these parameters did not change at the tibia (p=0.02 for difference between radius and tibia). In contrast, cortical porosity increased at the tibia (p<0.01) but not radius. Stiffness and failure load decreased at the radius (p<0.0001) but did not change at the tibia. Conclusions Cortical and trabecular changes in response to the PTH/ibandronate treatment combinations utilized in this study were different at the nonweight-bearing radius vs. the weight-bearing tibia, with more favorable overall changes at the tibia. Our findings support the possibility that weight bearing may optimize the effects of osteoporosis therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据